Enhanced Timeliness and Co-Administration of Meningitis B Vaccination in Children: Impact of Funding in Valencian Community, Spain-Reference-Cited by-同舟云学术

Enhanced Timeliness and Co-Administration of Meningitis B Vaccination in Children: Impact of Funding in Valencian Community, Spain

Published:2024-06-05 Issue:6 Volume:12 Page:623
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Juaneda Juan¹²^ORCID,Estrella-Porter Pablo¹³^ORCID,Blanco-Calvo Carolina¹⁴^ORCID,Orrico-Sánchez Alejandro⁵⁶⁷^ORCID,Lluch-Rodrigo José Antonio¹^ORCID,Pastor-Villalba Eliseo¹^ORCID

Affiliation:

1. Directorate-General for Public Health, Conselleria de Sanitat, 46010 Valencia, Spain

2. Preventive Medicine and Public Health, Hospital La Fe, 46026 Valencia, Spain

3. Preventive Medicine, Hospital Clínico Universitario, 46010 Valencia, Spain

4. Preventive Medicine, Hospital Universitario Doctor Peset, 46017 Valencia, Spain

5. Vaccines Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), 46017 Valencia, Spain

6. CIBER of Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain

7. Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain

Abstract

Public funding of vaccines may enhance vaccination rates, co-administration, and timeliness. The impacts of including the serogroup B meningococcus vaccine (MenB) into the national immunisation schedule on vaccination rates, co-administration rates, and timeliness were assessed using a population-based pre-funding (2022) and post-funding (2023) study design. MenB vaccination rates improved after funding and were in line with previously funded vaccines. Co-administration rates also increased significantly. Timely administration increased, protecting children at an early age. Public funding has a positive impact on vaccine accessibility and early protection. Consistent population characteristics highlight the role of funding.

Publisher

MDPI AG

Link

https://www.mdpi.com/2076-393X/12/6/623/pdf

Reference20 articles.

1. Enfermedad meningocócica invasiva. Temporada 2021–022;Boletín Epidemiológico Semanal,2023

2. Grupo de Trabajo Vacunación Frente a Enfermedad Meningocócica Invasiva por Serogrupo B de la Ponencia de Programa y Registro de Vacunaciones (2024, March 30). Recomendaciones de Vacunación Frente a la Enfermedad Meningo-Cócica Invasiva por Serogrupo B [Internet]. Available online: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/MenB_2022.pdf.

3. Lifetime costs of invasive meningococcal disease: A Markov model approach;Wang;Vaccine,2019

4. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children;Castilla;N. Engl. J. Med.,2023

5. Vademecum.es (2024, May 25). Bexsero Suspensión Inyectable en Jeringa Precargada [Internet]. Available online: https://www.vademecum.es/espana/medicamento/43040/bexsero-suspension-inyectable-en-jeringa-precargada.